Abstract PS5-07-02: NRG-BR008: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO)
Hyejoo Kang, Hanna Bandos, M. P. Mitchell, S. L. Puhalla et al.
Journal
Clinical Cancer Research
Topics
Breast Cancer Treatment Studies
article
Abstract PS5-07-02: NRG-BR008: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO)
Hyejoo Kang, Hanna Bandos, M. P. Mitchell, S. L. Puhalla, J. R. White, K. L. Bolton, T. B. Julian, P. A. Ganz, R. S. Cecchini, W. M. Sikov, E. P. Connolly, P. Y. Chen, E. Stringer-Reasor, A. J. Khan, K. R. Gergelis, L. Z. Braunstein, E. P. Mamounas
article en
Abstract
No abstract available for this paper.
Publication Tag
Clinical Cancer ResearchVol. 32(4_Supplement)
Institutions
Allegheny Health Network (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Loyola University Chicago (US), Washington University in St. Louis (US), Brown University (US), Beaumont Health (US), Columbia University Irving Medical Center (US), UCLA Health (US), University of Rochester Medical Center (US), University of Alabama at Birmingham (US), Florida Hospital Cancer Institute (US), The University of Kansas Cancer Center (US), UPMC Hillman Cancer Center (US), Women & Infants Hospital of Rhode Island (US), University of Pittsburgh Medical Center (US), Beaumont Hospital (US), NRG Oncology (US), NSABP Foundation (US)